Camurus AB (publ) (0RD1.L)
| Previous close | 684.92 |
| Open | 686.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 676.00 - 694.50 |
| 52-week range | 197.70 - 694.50 |
| Volume | |
| Avg. volume | 24,529 |
| Market cap | 31.993B |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.27 |
| Earnings date | 07 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCamurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of the
PR NewswireNew publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study1 comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal®/Brixadi®) to daily sublingual buprenorphine/naloxone (SL-BPN/NX). The data presented suggests the effectiveness in individuals with opioid dependence who use fentanyl, consistent with the results from the Phase 3 study.
